{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T00:12:58Z","timestamp":1789258378503,"version":"build-2803163510"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":222,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Morgan Adams Foundation Pediatric Research Program"},{"name":"National Health & Medical Research Council, Australia"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Atypical teratoid\/rhabdoid tumor (ATRT) is an aggressive central nervous system tumor mostly affecting young children. Improved and less toxic therapies for children with ATRT are imperative due to the toxicities associated with current treatments. Furthermore, existing therapies do not address the underlying genetic drivers of ATRT. In this study, we sought to determine whether exportin-1 (XPO1) is a genetic dependency and therapeutic target in ATRT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We utilized an integrative approach harnessing patient-derived ATRT cell lines, functional genomics, pharmacologic assays, transcriptomics, and in vivo intracranial xenograft models to systematically test the hypothesis that XPO1 is a novel dependency in ATRT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Analysis of RNA-sequencing datasets revealed high XPO1 expression in ATRT cells compared to other pediatric brain tumor cell lines. Both CRISPR\/Cas9 genetic knockdown and pharmacologic inhibition of XPO1 using 6 selective inhibitors of nuclear export (SINEs) in patient-derived atypical teratoid\/rhabdoid tumor (ATRT) cells led to significant reduction in cell viability and proliferation. Furthermore, we observed increased apoptosis, G0 phase cell cycle arrest, and upregulation of TP53 signaling pathways in cells treated with the SINE selinexor. Consistently, our transcriptomic data revealed the upregulation of apoptosis and TP53 signaling pathways and concomitant depletion of cell cycle gene sets. In vivo, selinexor in combination with radiation and cyclophosphamide led to significant reduction in tumor volume and increased animal survival in intracranial ATRT xenograft models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our data reveals XPO1 as a novel genetic dependency and potent therapeutic target in ATRT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/noajnl\/vdag209","type":"journal-article","created":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T11:53:23Z","timestamp":1786190003000},"source":"Crossref","is-referenced-by-count":0,"title":["Nuclear export inhibition activates TP53 pathways and is a potent therapeutic strategy in atypical teratoid rhabdoid tumors"],"prefix":"10.1093","volume":"8","author":[{"given":"Tessa O","family":"House","sequence":"first","affiliation":[{"name":"Children\u2019s Hospital Los Angeles, Cancer and Blood Disease Institute , Los Angeles"},{"name":"Children\u2019s Hospital Los Angeles, Saban Research Institute , Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Alimova","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Section of Pediatric Hematology\/Oncology\/Bone Marrow Transplant Research Laboratories, University of Colorado Denver, Anschutz Medical Campus"},{"name":"The Morgan Adams Foundation Pediatric Brain Tumor Research Program, Children\u2019s Hospital Colorado , Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawna","family":"Larsen","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital Los Angeles, Cancer and Blood Disease Institute , Los Angeles"},{"name":"Children\u2019s Hospital Los Angeles, Saban Research Institute , Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Murdock","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Section of Pediatric Hematology\/Oncology\/Bone Marrow Transplant Research Laboratories, University of Colorado Denver, Anschutz Medical Campus"},{"name":"The Morgan Adams Foundation Pediatric Brain Tumor Research Program, Children\u2019s Hospital Colorado , Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Pierce","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Section of Pediatric Hematology\/Oncology\/Bone Marrow Transplant Research Laboratories, University of Colorado Denver, Anschutz Medical Campus"},{"name":"The Morgan Adams Foundation Pediatric Brain Tumor Research Program, Children\u2019s Hospital Colorado , Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Breauna","family":"Brunt","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Section of Pediatric Hematology\/Oncology\/Bone Marrow Transplant Research Laboratories, University of Colorado Denver, Anschutz Medical Campus"},{"name":"The Morgan Adams Foundation Pediatric Brain Tumor Research Program, Children\u2019s Hospital Colorado , Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Tocci","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital Los Angeles, Cancer and Blood Disease Institute , Los Angeles"},{"name":"Children\u2019s Hospital Los Angeles, Saban Research Institute , Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Krykunenko","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital Los Angeles, Cancer and Blood Disease Institute , Los Angeles"},{"name":"Children\u2019s Hospital Los Angeles, Saban Research Institute , Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa","family":"Coppola","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital Los Angeles, Cancer and Blood Disease Institute , Los Angeles"},{"name":"Children\u2019s Hospital Los Angeles, Saban Research Institute , Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anat","family":"Erdreich-Epstein","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital Los Angeles, Cancer and Blood Disease Institute , Los Angeles"},{"name":"Children\u2019s Hospital Los Angeles, Saban Research Institute , Los Angeles"},{"name":"The Morgan Adams Foundation Pediatric Brain Tumor Research Program, Children\u2019s Hospital Colorado , Aurora"},{"name":"Department of Pediatrics, Keck School of Medicine of University of Southern California , Los Angeles"},{"name":"USC Norris Comprehensive Cancer Center , Los Angeles"},{"name":"Department of Pathology, Keck School of Medicine of University of Southern California , Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Firestein","sequence":"additional","affiliation":[{"name":"Centre for Cancer Research, Hudson Institute of Medical Research , Clayton, Victoria,","place":["Australia"]},{"name":"Department of Molecular and Translational Science, Faculty of Medicine, Nursing and Health Sciences, Monash University , Clayton, Victoria,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie J","family":"Serkova","sequence":"additional","affiliation":[{"name":"Department of Radiology, Colorado Animal Imaging Irradiation Shared Resource (AIISR), University of Colorado Anschutz Medical Campus , Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev","family":"Vibhakar","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Section of Pediatric Hematology\/Oncology\/Bone Marrow Transplant Research Laboratories, University of Colorado Denver, Anschutz Medical Campus"},{"name":"The Morgan Adams Foundation Pediatric Brain Tumor Research Program, Children\u2019s Hospital Colorado , Aurora"},{"name":"Center for Cancer and Blood Disorders, Children\u2019s Hospital , Aurora"},{"name":"Department of Neurosurgery, University of Colorado Denver , Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0540-4330","authenticated-orcid":false,"given":"Jessica W","family":"Tsai","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital Los Angeles, Cancer and Blood Disease Institute , Los Angeles"},{"name":"Children\u2019s Hospital Los Angeles, Saban Research Institute , Los Angeles"},{"name":"The Morgan Adams Foundation Pediatric Brain Tumor Research Program, Children\u2019s Hospital Colorado , Aurora"},{"name":"Department of Pediatrics, Keck School of Medicine of University of Southern California , Los Angeles"},{"name":"USC Norris Comprehensive Cancer Center , Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"key":"2026091220012561500_vdag209-B1","first-page":"74","article-title":"Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors","volume":"59","author":"Biegel","year":"1999","journal-title":"Cancer Res"},{"key":"2026091220012561500_vdag209-B2","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3171\/jns.1996.85.1.0056","article-title":"Central nervous system atypical teratoid\/rhabdoid tumors of infancy and childhood: definition of an entity","volume":"85","author":"Rorke","year":"1996","journal-title":"J Neurosurg"},{"key":"2026091220012561500_vdag209-B3","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1172\/JCI64400","article-title":"A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers","volume":"122","author":"Lee","year":"2012","journal-title":"J Clin Invest"},{"key":"2026091220012561500_vdag209-B4","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1093\/neuonc\/nov264","article-title":"Atypical teratoid\/rhabdoid tumors-current concepts, advances in biology, and potential future therapies","volume":"18","author":"Fruhwald","year":"2016","journal-title":"Neuro Oncol"},{"key":"2026091220012561500_vdag209-B5","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1200\/JCO.19.01776","article-title":"Efficacy of high-dose chemotherapy and three-dimensional conformal radiation for atypical teratoid\/rhabdoid tumor: a report from the children\u2019s oncology group trial ACNS0333","volume":"38","author":"Reddy","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026091220012561500_vdag209-B6","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1200\/JCO.2008.18.7724","article-title":"Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor","volume":"27","author":"Chi","year":"2009","journal-title":"J Clin Oncol"},{"key":"2026091220012561500_vdag209-B7","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1002\/pbc.25441","article-title":"Neurocognitive evaluation of long term survivors of atypical teratoid rhabdoid tumors (ATRT): the Canadian registry experience","volume":"62","author":"Lafay-Cousin","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"2026091220012561500_vdag209-B8","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1093\/neuonc\/noaa046","article-title":"Advancing biology-based therapeutic approaches for atypical teratoid rhabdoid tumors","volume":"22","author":"Hoffman","year":"2020","journal-title":"Neuro Oncol"},{"key":"2026091220012561500_vdag209-B9","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1177\/1093526619869154","article-title":"Loss of BRG1 (SMARCA4) immunoexpression in a pediatric non-central nervous system tumor cohort","volume":"23","author":"Saunders","year":"2020","journal-title":"Pediatr Dev Pathol"},{"key":"2026091220012561500_vdag209-B10","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.ccell.2016.11.003","article-title":"Integrated (epi)-genomic analyses identify subgroup-specific therapeutic targets in CNS rhabdoid tumors","volume":"30","author":"Torchia","year":"2016","journal-title":"Cancer Cell"},{"key":"2026091220012561500_vdag209-B11","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S1470-2045(15)70114-2","article-title":"Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysis","volume":"16","author":"Torchia","year":"2015","journal-title":"Lancet Oncol"},{"key":"2026091220012561500_vdag209-B12","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1093\/neuonc\/noz235","article-title":"Molecular subgrouping of atypical teratoid\/rhabdoid tumors-a reinvestigation and current consensus","volume":"22","author":"Ho","year":"2020","journal-title":"Neuro Oncol"},{"key":"2026091220012561500_vdag209-B13","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.ccell.2016.02.001","article-title":"Atypical teratoid\/rhabdoid tumors are comprised of three epigenetic subgroups with distinct enhancer landscapes","volume":"29","author":"Johann","year":"2016","journal-title":"Cancer Cell"},{"key":"2026091220012561500_vdag209-B14","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1200\/JCO.2004.07.073","article-title":"Central nervous system atypical teratoid\/rhabdoid tumor: results of therapy in children enrolled in a registry","volume":"22","author":"Hilden","year":"2004","journal-title":"J Clin Oncol"},{"key":"2026091220012561500_vdag209-B15","doi-asserted-by":"publisher","first-page":"7152","DOI":"10.1200\/JCO.2005.01.214","article-title":"Intellectual and functional outcome of children 3 years old or younger who have CNS malignancies","volume":"23","author":"Fouladi","year":"2005","journal-title":"J Clin Oncol"},{"key":"2026091220012561500_vdag209-B16","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/pbc.24648","article-title":"Intensive induction chemotherapy followed by myeloablative chemotherapy with autologous hematopoietic progenitor cell rescue for young children newly-diagnosed with central nervous system atypical teratoid\/rhabdoid tumors: the head start III experience","volume":"61","author":"Zaky","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"2026091220012561500_vdag209-B17","doi-asserted-by":"publisher","first-page":"100880","DOI":"10.1016\/j.neo.2023.100880","article-title":"Recent progress and novel approaches to treating atypical teratoid rhabdoid tumor","volume":"37","author":"Alva","year":"2023","journal-title":"Neoplasia"},{"key":"2026091220012561500_vdag209-B18","doi-asserted-by":"publisher","first-page":"4664","DOI":"10.21037\/tcr-21-1646","article-title":"Pan-cancer analysis reveals the roles of XPO1 in predicting prognosis and tumorigenesis","volume":"10","author":"Zhao","year":"2021","journal-title":"Transl Cancer Res"},{"key":"2026091220012561500_vdag209-B19","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1038\/leu.2013.172","article-title":"Genome-wide studies in multiple myeloma identify XPO1\/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276","volume":"27","author":"Schmidt","year":"2013","journal-title":"Leukemia"},{"key":"2026091220012561500_vdag209-B20","doi-asserted-by":"publisher","first-page":"21289","DOI":"10.18632\/oncotarget.25088","article-title":"CRM1\/XPO1 expression in pancreatic adenocarcinoma correlates with survivin expression and the proliferative activity","volume":"9","author":"Saulino","year":"2018","journal-title":"Oncotarget"},{"key":"2026091220012561500_vdag209-B21","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.31557\/APJCP.2019.20.12.3747","article-title":"Association of XPO1 overexpression with NF-kappaB and Ki67 in colorectal cancer","volume":"20","author":"Aladhraei","year":"2019","journal-title":"Asian Pac J Cancer Prev"},{"key":"2026091220012561500_vdag209-B22","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1111\/cas.12430","article-title":"Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma","volume":"105","author":"Yoshimura","year":"2014","journal-title":"Cancer Sci"},{"key":"2026091220012561500_vdag209-B23","doi-asserted-by":"publisher","first-page":"4166","DOI":"10.1182\/blood-2012-08-447581","article-title":"Prognostic impact and targeting of CRM1 in acute myeloid leukemia","volume":"121","author":"Kojima","year":"2013","journal-title":"Blood"},{"key":"2026091220012561500_vdag209-B24","doi-asserted-by":"publisher","first-page":"4621","DOI":"10.1182\/blood-2012-05-429506","article-title":"Selective inhibitors of nuclear export show that CRM1\/XPO1 is a target in chronic lymphocytic leukemia","volume":"120","author":"Lapalombella","year":"2012","journal-title":"Blood"},{"key":"2026091220012561500_vdag209-B25","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/leu.2012.219","article-title":"Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells","volume":"27","author":"Etchin","year":"2013","journal-title":"Leukemia"},{"key":"2026091220012561500_vdag209-B26","doi-asserted-by":"publisher","first-page":"4142","DOI":"10.1200\/JCO.2015.65.3949","article-title":"First-in-class, first-in-human phase I study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors","volume":"34","author":"Abdul Razak","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026091220012561500_vdag209-B27","doi-asserted-by":"publisher","first-page":"e511","DOI":"10.1016\/S2352-3026(20)30120-4","article-title":"Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial","volume":"7","author":"Kalakonda","year":"2020","journal-title":"Lancet Haematol"},{"key":"2026091220012561500_vdag209-B28","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1182\/blood-2016-11-750158","article-title":"A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia","volume":"129","author":"Garzon","year":"2017","journal-title":"Blood"},{"key":"2026091220012561500_vdag209-B29","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.1182\/blood-2016-11-750174","article-title":"Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma","volume":"129","author":"Kuruvilla","year":"2017","journal-title":"Blood"},{"key":"2026091220012561500_vdag209-B30","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","article-title":"Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial","volume":"396","author":"Grosicki","year":"2020","journal-title":"Lancet"},{"key":"2026091220012561500_vdag209-B31","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1182\/blood-2017-08-797886","article-title":"Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia","volume":"131","author":"Chen","year":"2018","journal-title":"Blood"},{"key":"2026091220012561500_vdag209-B32","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1158\/1535-7163.MCT-18-1319","article-title":"Exportin 1 inhibition induces nerve growth factor receptor expression to inhibit the NF-kappaB pathway in preclinical models of pediatric high-grade glioma","volume":"19","author":"DeSisto","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"2026091220012561500_vdag209-B33","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1158\/1078-0432.CCR-24-2754","article-title":"Phase I trial of selinexor in pediatric recurrent\/refractory solid and CNS tumors (ADVL1414): a children\u2019s oncology group phase I consortium trial","volume":"31","author":"Green","year":"2025","journal-title":"Clin Cancer Res"},{"key":"2026091220012561500_vdag209-B34","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","article-title":"Defining a cancer dependency map","volume":"170","author":"Tsherniak","year":"2017","journal-title":"Cell"},{"key":"2026091220012561500_vdag209-B35","doi-asserted-by":"publisher","first-page":"20380","DOI":"10.1073\/pnas.0810485105","article-title":"Highly parallel identification of essential genes in cancer cells","volume":"105","author":"Luo","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026091220012561500_vdag209-B36","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1186\/s13059-024-03438-w","article-title":"Functional screening reveals genetic dependencies and diverging cell cycle control in atypical teratoid rhabdoid tumors","volume":"25","author":"Merk","year":"2024","journal-title":"Genome Biol"},{"key":"2026091220012561500_vdag209-B37","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.ccell.2023.03.007","article-title":"Generation and multi-dimensional profiling of a childhood cancer cell line atlas defines new therapeutic opportunities","volume":"41","author":"Sun","year":"2023","journal-title":"Cancer Cell"},{"key":"2026091220012561500_vdag209-B38","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1158\/1541-7786.MCR-24-0926","article-title":"SIRT2 regulates the SMARCB1 loss-driven differentiation block in ATRT","volume":"23","author":"Alimova","year":"2025","journal-title":"Mol Cancer Res"},{"key":"2026091220012561500_vdag209-B39","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41587-019-0032-3","article-title":"CRISPResso2 provides accurate and rapid genome editing sequence analysis","volume":"37","author":"Clement","year":"2019","journal-title":"Nat Biotechnol"},{"key":"2026091220012561500_vdag209-B40","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.184601","article-title":"Multidimensional, integrative profiling identifies BCL2L1 methylation as a predictor of MCL1 dependency in pediatric malignancies","volume":"10","author":"Adjumain","year":"2025","journal-title":"JCI Insight"},{"key":"2026091220012561500_vdag209-B41","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","article-title":"Trimmomatic: a flexible trimmer for illumina sequence data","volume":"30","author":"Bolger","year":"2014","journal-title":"Bioinformatics"},{"key":"2026091220012561500_vdag209-B42","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"2026091220012561500_vdag209-B43","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1093\/bioinformaics\/bty895","article-title":"Heavy-tailed prior distributions for sequence count data: removing the noise and preserving large differences","volume":"35","author":"Zhu","year":"2019","journal-title":"Bioinformatics"},{"key":"2026091220012561500_vdag209-B44","doi-asserted-by":"publisher","first-page":"060012","DOI":"10.1101\/060012","article-title":"Fast gene set enrichment analysis","author":"Korotkevich","year":"2021","journal-title":"bioRxiv"},{"key":"2026091220012561500_vdag209-B45","doi-asserted-by":"publisher","first-page":"30773","DOI":"10.18632\/oncotarget.25637","article-title":"Selinexor reduces the expression of DNA damage repair proteins and sensitizes cancer cells to DNA damaging agents","volume":"9","author":"Kashyap","year":"2018","journal-title":"Oncotarget"},{"key":"2026091220012561500_vdag209-B46","doi-asserted-by":"publisher","first-page":"wuaf018","DOI":"10.1093\/neuped\/wuaf018","article-title":"Targeting the p53 pathway to treat atypical teratoid rhabdoid tumors","volume":"2","author":"Refaat","year":"2026","journal-title":"Neurooncol Pediatr"},{"key":"2026091220012561500_vdag209-B47","doi-asserted-by":"publisher","first-page":"21655","DOI":"10.1073\/pnas.0912384106","article-title":"CRM1 mediates nuclear-cytoplasmic shuttling of mature microRNAs","volume":"106","author":"Castanotto","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026091220012561500_vdag209-B48","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1038\/emboj.2010.82","article-title":"The nuclear export receptor XPO-1 supports primary miRNA processing in C. elegans and Drosophila","volume":"29","author":"Bussing","year":"2010","journal-title":"Embo J"},{"key":"2026091220012561500_vdag209-B49","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.2174\/1389450111314100002","article-title":"Nuclear export mediated regulation of microRNAs: potential target for drug intervention","volume":"14","author":"Muqbil","year":"2013","journal-title":"Curr Drug Targets"}],"container-title":["Neuro-Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/noa\/advance-article-pdf\/doi\/10.1093\/noajnl\/vdag209\/70612840\/vdag209.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/8\/1\/vdag209\/70612840\/vdag209.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/8\/1\/vdag209\/70612840\/vdag209.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T00:01:32Z","timestamp":1789257692000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/noa\/article\/doi\/10.1093\/noajnl\/vdag209\/8759019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,12]]}},"URL":"https:\/\/doi.org\/10.1093\/noajnl\/vdag209","relation":{},"ISSN":["2632-2498"],"issn-type":[{"value":"2632-2498","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2026,1]]},"article-number":"vdag209"}}